Oppenheimer Cuts Price Target on United Rentals (URI) Following 2Q15 Results and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
RBC Capital Downgrades United Rentals (URI) to Outperform
July 24, 2015 7:05 AM EDTRBC Capital downgraded United Rentals (NYSE: URI) from Top Pick to Outperform with a price target of $94.00 (from $110.00).
For an analyst ratings summary and ratings history on United Rentals click here. For more ratings news on United Rentals click here.
Shares of United Rentals closed at $66.98 yesterday.
... MoreNotable 52-Week Highs and Lows 7/23: (ITEK) (HBAN) (FTNT) High; (URI) (UNP) (CAB) Low
July 23, 2015 3:48 PM EDT52-Week High:Inotek Pharmaceuticals (Nasdaq: ITEK) $16.75. Inotek Pharmaceuticals ripping higher Thursday after the company announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on feedback from a recent End of Phase 2 meeting with the US Food and Drug Administration (FDA), Inotek is in final preparation stages to commence its first Phase 3 trial to support a New Drug Application (NDA) for trabodenoson.
Pre-Open Stock Movers 07/23: (CARA) (SNDK) (CRUS) Higher; (CVA) (URI) (SCSS) Lower (more...)
July 23, 2015 9:30 AM EDTInotek Pharmaceuticals Corporation (NASDAQ: ITEK) 51% HIGHER; announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on... More
